DB00398 : targeting multiple tyrosine kinases in cancer . DB00398 ( BAY 43-9006 , NexavarÂ® ) is an oral multiple tyrosine kinase inhibitor . Main targets are receptor tyrosine kinase pathways frequently deregulated in cancer such as the Raf-Ras pathway , vascular endothelial growth factor ( P15692 ) pathway , and P07333 -like tyrosine kinase 3 ( P36888 ) . DB00398 was approved by the FDA in fast track for advanced renal cell cancer and hepatocellular cancer and shows good clinical activity in thyroid cancer . Multiple clinical trials are undertaken to further investigate the role of sorafenib alone or in combination for the treatment of various tumor entities .